APA (7th ed.) Citation

Wenn, K., & Müller, M. C. (2015). Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib: Letters to the editor. Leukemia, 29(12), . https://doi.org/10.1038/leu.2015.245

Chicago Style (17th ed.) Citation

Wenn, K., and Martin Christian Müller. "Telomere Length at Diagnosis of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Identifies a Subgroup with Favourable Prognostic Parameters and Molecular Response According to the ELN Criteria After 12 Months of Treatment with Nilotinib: Letters to the Editor." Leukemia 29, no. 12 (2015). https://doi.org/10.1038/leu.2015.245.

MLA (9th ed.) Citation

Wenn, K., and Martin Christian Müller. "Telomere Length at Diagnosis of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Identifies a Subgroup with Favourable Prognostic Parameters and Molecular Response According to the ELN Criteria After 12 Months of Treatment with Nilotinib: Letters to the Editor." Leukemia, vol. 29, no. 12, 2015, https://doi.org/10.1038/leu.2015.245.